Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria.
Travel Med Infect Dis. 2010 Jul;8(4):251-6. doi: 10.1016/j.tmaid.2010.05.007. Epub 2010 Jun 25.
The increase of TBE cases in Europe has become a problem of international public health and travel medicine, because it is not only of concern for endemic areas, but also for visitors from non-endemic countries. Although highly effective modern vaccines are on the market in 28 European countries, there are still 7, mainly Eastern European, countries with no or an uncertain number of cases and without licensed modern vaccines. The prevailing danger for travellers, however, lies in underestimation and not awareness of the disease by public authorities, travel agencies and by the travellers themselves, a lack of mandatory notifications and sometimes a lack of financial resources. Outside Europe TBE has mostly not been recognized as a travel associated disease. Recommendation for travellers to endemic countries and suggestions to extra-European travellers and health authorities as well as vaccination advices are summarized in this paper.
欧洲 TBE 病例的增加已成为国际公共卫生和旅行医学的一个问题，因为它不仅是疫区关注的问题，也是来自非疫区国家的游客关注的问题。尽管在 28 个欧洲国家有高效的现代疫苗上市，但仍有 7 个主要是东欧国家，没有或不确定有多少病例，也没有获得许可的现代疫苗。然而，旅行者面临的主要危险是公共当局、旅行社和旅行者自身低估和不了解这种疾病，缺乏强制性通知，有时还缺乏资金。在欧洲以外，TBE 大多没有被认为是一种与旅行相关的疾病。本文总结了对疫区旅行者的建议、对非欧洲旅行者和卫生当局的建议以及接种疫苗的建议。
